Chlorotrianisene

产品说明书

Print
Chemical Structure| 569-57-3 同义名 : 氯烯雌醚 ;NSC 10108; tri-p-anisylchloroethylene; Rianil; Metace; Anisene; Hormonisene; Clorotrisin; Clorestrolo; Khlortrianizen; Chlorotrianizen; Chlorestrolo; Chlorotrianisine; Chlortrianizen; Chlortrianisestrol; CTA; TACE; tris(p-methoxyphenyl)chloroethylene
CAS号 : 569-57-3
货号 : A640644
分子式 : C23H21ClO3
纯度 : 99%+
分子量 : 380.86
MDL号 : MFCD00048044
存储条件：

Pure form Inert atmosphere, store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
描述 Chlorotrianisene (TACE), a synthetic and non-steroidal estrogen, has special estrogenic properties and is a modulator of estrogen receptor. Chlorotrianisene treatment (4 mL/kg, i.p. daily) on ovariectomized Wistar female rat for 45 days could inhibit bone loss and delay the atrophy of uterus induced by ovariectomy[3]. It was found that Chlorotrianisene potently inhibits the enzyme COX-1, which is unrelated by sequence to the primary nuclear hormone receptor of this drug, the estrogen receptor[4]. There was a significant decrease in antithrombin III levels on the third postpartum day in patients who elected lactation suppression and received chlorotriansene, 72 mg every 12 h, compared to those who received placebo[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00834158 Hepatocellular Carcinoma Not Applicable Completed - China ... 展开 >> Eastern Hepatobiliary Surgery Hospital Shanghai, China, 200438 收起 <<
NCT02557490 Colon Cancer Liver Metastasis Phase 4 Unknown December 2017 China, Beijing ... 展开 >> Beijing Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Zhu Xu, Master    0086-10-88195476    zhux387@263.net    Principal Investigator: Zhu Xu, Master 收起 <<
NCT02147301 Hepatocellular Carcinoma ... 展开 >> Chemoembolization 收起 << Phase 2 Enrolling by invitation - United States, California ... 展开 >> University of California San Francisco San Francisco, California, United States, 94143 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.13mL

2.63mL

1.31mL

26.26mL

5.25mL

2.63mL
参考文献

[1]Zhang J, Yang W, et al. [Prevention of bone loss by chlorotrianisene in oophorectomized rats] . Zhonghua Fu Chan Ke Za Zhi. 1997 Sep;32(9):535-7. Chinese.

[2]Powers CA, Hatala MA, et al. Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Mol Cell Endocrinol. 1989 Sep;66(1):93-100.

[3]Zhang J, Yang W, Shen Z. [Prevention of bone loss by chlorotrianisene in oophorectomized rats]. Zhonghua Fu Chan Ke Za Zhi. 1997 Sep;32(9):535-7. Chinese. PMID: 9639753.

[4]Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Côté S, Shoichet BK, Urban L. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 10;486(7403):361-7. doi: 10.1038/nature11159. PMID: 22722194; PMCID: PMC3383642.

[5]Niebyl JR, Bell WR, Schaaf ME, Blake DA, Dubin NH, King TM. The effect of chlorotrianisene as postpartum lactation suppression on blood coagulation factors. Am J Obstet Gynecol. 1979 Jul 1;134(5):518-22. doi: 10.1016/0002-9378(79)90832-9. PMID: 453287.